Literature DB >> 21224066

Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex.

Whitney E Parker1, Ksenia A Orlova, Gregory G Heuer, Marianna Baybis, Eleonora Aronica, Michael Frost, Michael Wong, Peter B Crino.   

Abstract

Epidermal growth factor (EGF), hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF) regulate angiogenesis and cell growth in the developing brain. EGF, HGF, and VEGF modulate the activity of the mammalian target of rapamycin (mTOR) cascade, a pathway regulating cell growth that is aberrantly activated in tuberous sclerosis complex (TSC). We hypothesized that expression of EGF, HGF, VEGF, and their receptors EGFR, c-Met, and Flt-1, respectively, would be altered in TSC. We show by cDNA array and immunohistochemical analysis that EGF, EGFR, HGF, c-Met, and VEGF, but not Flt-1, mRNA, and protein expression was up-regulated in Tsc1 conditional knockout (Tsc1(GFAP)CKO) mouse cortex. Importantly, these alterations closely predicted enhanced expression of these proteins in tuber and subependymal giant cell astrocytoma (SEGA) specimens in TSC. Expression of EGF, EGFR, HGF, c-Met, and VEGF protein, as well as hypoxia inducible factor-1α, a transcription factor that regulates VEGF levels and is also modulated by mTOR cascade activity, was enhanced in SEGAs (n = 6) and tubers (n = 10) from 15 TSC patients. Enhanced expression of these growth factors and growth factor receptors in human SEGAs and tubers and in the Tsc1(GFAP)CKO mouse may account for enhanced cellular growth and proliferation in tubers and SEGAs and provides potential target molecules for therapeutic development in TSC. Copyright Â
© 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21224066      PMCID: PMC3069836          DOI: 10.1016/j.ajpath.2010.11.031

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  Epilepsy surgery in children with tuberous sclerosis complex: presurgical evaluation and outcome.

Authors:  S Koh; P Jayakar; C Dunoyer; S E Whiting; T J Resnick; L A Alvarez; G Morrison; J Ragheb; A Prats; P Dean; J Gilman; M S Duchowny
Journal:  Epilepsia       Date:  2000-09       Impact factor: 5.864

2.  Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis.

Authors:  P A Nguyen-Vu; I Fackler; A Rust; J E DeClue; C A Sander; M Volkenandt; M Flaig; R S Yeung; R Wienecke
Journal:  J Cutan Pathol       Date:  2001-10       Impact factor: 1.587

Review 3.  Tuberous sclerosis complex.

Authors:  S P Sparagana; E S Roach
Journal:  Curr Opin Neurol       Date:  2000-04       Impact factor: 5.710

4.  Biological behavior and tumorigenesis of subependymal giant cell astrocytomas.

Authors:  S K Kim; K C Wang; B K Cho; H W Jung; Y J Lee; Y S Chung; J Y Lee; S H Park; Y M Kim; G Choe; J G Chi
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

5.  Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms.

Authors:  Jack L Arbiser; Daniel Brat; Steve Hunter; Jeanine D'Armiento; Elizabeth P Henske; Zoya K Arbiser; Xianhe Bai; Gerald Goldberg; Cynthia Cohen; Sharon W Weiss
Journal:  J Am Acad Dermatol       Date:  2002-03       Impact factor: 11.527

6.  Differential cellular expression of neurotrophins in cortical tubers of the tuberous sclerosis complex.

Authors:  R Kyin; Y Hua; M Baybis; B Scheithauer; D Kolson; E Uhlmann; D Gutmann; P B Crino
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

7.  Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex.

Authors:  Patrick F Bolton; Rebecca J Park; J Nicholas P Higgins; Paul D Griffiths; Andrew Pickles
Journal:  Brain       Date:  2002-06       Impact factor: 13.501

Review 8.  Neuropathology of tuberous sclerosis.

Authors:  M Mizuguchi; S Takashima
Journal:  Brain Dev       Date:  2001-11       Impact factor: 1.961

9.  Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

Authors:  Ling-Hui Zeng; Lin Xu; David H Gutmann; Michael Wong
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

10.  Impact of rapamycin on liver regeneration.

Authors:  Daniel Palmes; Andree Zibert; Tymotheus Budny; Ralf Bahde; Evgeny Minin; Linus Kebschull; Jens Hölzen; Hartmut Schmidt; Hans-Ullrich Spiegel
Journal:  Virchows Arch       Date:  2008-05       Impact factor: 4.064

View more
  19 in total

Review 1.  mTOR signaling in epilepsy: insights from malformations of cortical development.

Authors:  Peter B Crino
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

2.  Hypervascularization in mTOR-dependent focal and global cortical malformations displays differential rapamycin sensitivity.

Authors:  Longbo Zhang; Tianxiang Huang; Shannon Teaw; Angélique Bordey
Journal:  Epilepsia       Date:  2019-05-24       Impact factor: 5.864

Review 3.  Vascular hyperpermeability as a hallmark of phacomatoses: is the etiology angiogenesis related to or comparable with mechanisms seen in inflammatory pathways? Part II: angiogenesis- and inflammation-related molecular pathways, tumor-associated macrophages, and possible therapeutic implications: a comprehensive review.

Authors:  Yosef Laviv; Burkhard Kasper; Ekkehard M Kasper
Journal:  Neurosurg Rev       Date:  2017-03-11       Impact factor: 3.042

Review 4.  Epilepsy related to developmental tumors and malformations of cortical development.

Authors:  Eleonora Aronica; Peter B Crino
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

5.  A vascular model of Tsc1 deficiency accelerates renal tumor formation with accompanying hemangiosarcomas.

Authors:  Jarrett D Leech; Stephen H T Lammers; Sam Goldman; Neil Auricchio; Roderick T Bronson; David J Kwiatkowski; Mustafa Sahin
Journal:  Mol Cancer Res       Date:  2014-12-29       Impact factor: 5.852

Review 6.  The molecular biology of WHO grade I astrocytomas.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

7.  Hypoxia-inducible factor 1a is a Tsc1-regulated survival factor in newborn neurons in tuberous sclerosis complex.

Authors:  David M Feliciano; Shiliang Zhang; Jennifer L Quon; Angélique Bordey
Journal:  Hum Mol Genet       Date:  2013-01-24       Impact factor: 6.150

8.  Fetal brain mTOR signaling activation in tuberous sclerosis complex.

Authors:  Victoria Tsai; Whitney E Parker; Ksenia A Orlova; Marianna Baybis; Anthony W S Chi; Benjamin D Berg; Jacqueline F Birnbaum; Jacqueline Estevez; Kei Okochi; Harvey B Sarnat; Laura Flores-Sarnat; Eleonora Aronica; Peter B Crino
Journal:  Cereb Cortex       Date:  2012-10-18       Impact factor: 5.357

9.  Inhibition of EGFR/MAPK signaling reduces microglial inflammatory response and the associated secondary damage in rats after spinal cord injury.

Authors:  Wen-Sheng Qu; Dai-Shi Tian; Zhi-Bao Guo; Jun Fang; Qiang Zhang; Zhi-Yuan Yu; Min-Jie Xie; Hua-Qiu Zhang; Jia-Gao Lü; Wei Wang
Journal:  J Neuroinflammation       Date:  2012-07-23       Impact factor: 8.322

Review 10.  Histological Patterns of Skin Lesions in Tuberous Sclerosis Complex: A Panorama.

Authors:  Marine Cascarino; Stéphanie Leclerc-Mercier
Journal:  Dermatopathology (Basel)       Date:  2021-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.